Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003
Comparison of the bronchoprotective effects of two salbutamol suplphate HFA pMDI using methacholine challenge testing Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Evaluation of the systemic pharmacodynamic effects of two HFA formulations of Salmeterol xinafoate/Fluticasone propionate HFA pMDI 25/250 mcg Source: International Congress 2017 – Inhalers and their use Year: 2017
Device preference and efficacy of formoterol aerolizer and salbutamol MDI in children with asthma Source: Eur Respir J 2003; 22: Suppl. 45, 134s Year: 2003
Formoterol hydrofluoroalkane (HFA) pMDI has as rapid an onset of action as salbutamol HFA pMDI in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 285s Year: 2003
Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Effect of montelukast or salmeterol added to inhaled fluticasone on response to albuterol in children with exercise-induced bronchoconstriction Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler Source: Eur Respir J 2001; 17: 225-232 Year: 2001
Budesonide pharmacokinetics and systemic effects at steady state via HFA pMDI, CFC pMDI and Turbuhaler® in healthy volunteers Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
A pMDI formulation of levosalbutamol produces an equivalent bronchodilator response as racemic salbutamol at half the dose Source: Eur Respir J 2005; 26: Suppl. 49, 122s Year: 2005
Formoterol turbuhaler is as effective as salbutamol diskus in relieving adenosine- induced bronchoconstriction Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004
Bronchodilation from formoterol and terbutaline has similar onset of action in asthmatic children Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Comparison of the effects of beclomethasone HFA (BDP- HFA) pMDI with beclomethasone CFC (BDP-CFC) pMDI on 10-hour urinary cortisol in healthy subjects Source: Annual Congress 2008 - Advances in the treatment and pathogenesis of pulmonary diseases Year: 2008
Systemic activity of beclometasone dipropionate HFA and CFC formulations in metered dose inhalers assessed by knemometry Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
The acute effect of inhaled salbutamol and ipratropium on microvascular function Source: International Congress 2018 – Basic pharmacology Year: 2018
Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions Source: Eur Respir J 2006; 28: Suppl. 50, 211s Year: 2006
Ipratropium bromide HFA propellant inhaler has equivalent safety and efficacy to the marketed CFC propellant inhaler in bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Attenuation of exercise-induced bronchoconstriction with montelukast or salmeterol added to inhaled fluticasone in children Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 58s Year: 2002